entertainment -WSS

entertainment

author：knowledge 2025-08-04 12:36:45 - browse：51

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Where does female orgasm come from? Scientists think they know

leisure time

focus

WSS

Burning questions about Delta and the next phase of the Covid pandemic

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

My superpower is killing ticks

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

What Henrietta Lacks settlement says about racism in medicine

What the cancer research community can learn from the Covid response

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Virginia high school admissions case could be legal follow

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Guidelines to prevent youth baseball injuries need more muscle

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Walensky prepares to leave CDC — and Congress — behind

Malaysia cuts short music fest after British band slams anti

Moonlake's readout produced a cash windfall. Risks remain

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

leisure time

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

Statins reduce cardiovascular risk in people living with HIV

FDA approves first blood sugar monitor without finger pricks

What Henrietta Lacks settlement says about racism in medicine

New requirements coming in 2024 for Americans traveling to Europe

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Wikipedia

leisure time

focus

hotspot